Long-term outcomes of deep brain stimulation in Parkinson disease
P Limousin, T Foltynie - Nature Reviews Neurology, 2019 - nature.com
The efficacy of deep brain stimulation (DBS) for Parkinson disease (PD) is well established
for up to 1 or 2 years, but long-term outcome data are still limited. In this Review, we critically …
for up to 1 or 2 years, but long-term outcome data are still limited. In this Review, we critically …
Gastrointestinal dysfunction in Parkinson's disease
Our understanding of dysfunction of the gastrointestinal system in patients with Parkinson's
disease has increased substantially in the past decade. The entire gastrointestinal tract is …
disease has increased substantially in the past decade. The entire gastrointestinal tract is …
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double …
Background Levodopa is the most effective therapy for Parkinson's disease, but chronic
treatment is associated with the development of potentially disabling motor complications …
treatment is associated with the development of potentially disabling motor complications …
Develo** consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi …
A Antonini, AJ Stoessl, LS Kleinman… - … medical research and …, 2018 - Taylor & Francis
Background: Lack of a global consensus on the definition of advanced Parkinson's disease
(APD) and considerations for timing of device-aided therapies may result in heterogeneity in …
(APD) and considerations for timing of device-aided therapies may result in heterogeneity in …
Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting
In last two decades, the lipid nanocarriers have been extensively investigated for their drug
targeting efficiency towards the critical areas of the human body like CNS, cardiac region …
targeting efficiency towards the critical areas of the human body like CNS, cardiac region …
Medical and surgical management of advanced Parkinson's disease
A Antonini, E Moro, C Godeiro… - Movement …, 2018 - Wiley Online Library
Advanced Parkinson's disease is characterized by the presence of motor fluctuations,
various degree of dyskinesia, and disability with functional impact on activities of daily living …
various degree of dyskinesia, and disability with functional impact on activities of daily living …
[HTML][HTML] Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease …
P Odin, KR Chaudhuri, JT Slevin, J Volkmann… - Parkinsonism & Related …, 2015 - Elsevier
Navigate PD was an educational program established to supplement existing guidelines
and provide recommendations on the management of Parkinson's disease (PD) refractory to …
and provide recommendations on the management of Parkinson's disease (PD) refractory to …
Expert consensus group report on the use of apomorphine in the treatment of Parkinson's disease–clinical practice recommendations
C Trenkwalder, KR Chaudhuri, PJG Ruiz… - Parkinsonism & related …, 2015 - Elsevier
Extensive published evidence supports the use of subcutaneously-administered
apomorphine as an effective therapy for Parkinson's disease (PD) but to date no consensus …
apomorphine as an effective therapy for Parkinson's disease (PD) but to date no consensus …
Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life
A Manson, P Stirpe, A Schrag - Journal of Parkinson's disease, 2012 - content.iospress.com
Levodopa-induced dyskinesias (LID) belong to the most common dose-limiting adverse
effects of levodopa therapy.“Peak-dose” LID occur with the maximum effect of …
effects of levodopa therapy.“Peak-dose” LID occur with the maximum effect of …
A sco** review of neurodegenerative manifestations in explainable digital phenoty**
Neurologists nowadays no longer view neurodegenerative diseases, like Parkinson's and
Alzheimer's disease, as single entities, but rather as a spectrum of multifaceted symptoms …
Alzheimer's disease, as single entities, but rather as a spectrum of multifaceted symptoms …